Why I will ask my doctor to use a new breast cancer test

Veronica Combs has written a very enlightening piece about the ForeCYTE Breast Health Test – read her thoughts below:

May 15, 2013 4:04 pm by 

Veronica Combs

I do not get annual mammograms, even though I am 42. I got a baseline in my late 30s in preparation for regular mammograms in a few years. That was before the USPSTF revised its recommendations about the benefits of mammograms for women my age. The more I read about overdiagnosis and overtreatment, the more I agreed with the task force.

The last time I went in for my annual OBGYN check up, my doctor and I argued about this. She had recently helped both her mother and sister through a breast cancer diagnosis, and refuted my “no family history” argument with: “We have no family history and my mom just had a double mastectomy. Don’t talk to me about family history.”

After writing about Atossa Genetics and the ForeCYTE test, I am back on board with annual screening. When I go in for this year’s exam, I will request this test, pay for it myself if necessary and search until I find a doctor who will use it.

It is not an exaggeration to say that this test could erase breast cancer by 2020, as the company founder Dr. Steven Quay predicts. It absolutely has the potential to reduce breast cancer rates just as pap smears have cut rates of cervical cancer.

The test analyzes nipple aspirate fluid for cancerous and pre-cancerous cells. The test everything that modern medicine should be:

  • Minimal – there is no radiation
  • Non-invasive – there are no needles
  • Convenient – it can be added to the standard annual OBGYN exam, which means no extra trip to a mammogram clinic
  • Smart – it tells you exactly what is going on in the cells of your breasts
  • Targeted to the individual – women and doctors will know exactly who needs treatment and who doesn’t

It even erases the “but it hurts” objection to mammograms. Quay said that on a discomfort scale used in clinical trials, mammograms are rated 4.5, breast feeding is 2.1, and his test is 1.5. Thecollection process can be done in a doctor’s office and takes only a few minutes.

Atossa is also working on a new treatment for women who do have early signs of cancer. The idea is to put a chemoprevention drug in the segment of a breast undergoing pre-cancerous changes. This is the ideal replacement for the “cut, burn, poison” approach to treating breast cancer.

We have achieved “awareness.” It’s time for Komen and every other organization focused on breast cancer to start supporting smarter screenings and treatments like Atossa’s test and for women of all ages to start asking their doctors to use it.

Read more: http://medcitynews.com/2013/05/no-joke-this-new-test-could-erase-breast-cancer-by-2020/#ixzz2TPSeBOUC

Detecting breast cancer in dense breasts

Visit the link below to read an article written by Dr. Steven Quay on news-medical.net, he is the medical director of the National Reference Laboratory for Breast Health.


Here is an excerpt:

I believe there’s even a better approach, one that solves the dense breast detection problem completely—and makes it possible to spot signs of precancerous changes up to eight years before a tumor would show up on a mammogram or an ultrasound.

Atossa Genetics Launches Nationwide Awareness Program for Breast Cancer Prevention Test

Atossa Genetics, Inc.

New Video Highlights Atossa’s ForeCYTE Breast Health Test and Its Ability to Find Precancerous Conditions up to Eight Years Before Mammograms Find Cancer

SEATTLE, WA–(Marketwired – Apr 15, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced the launch of a new National Awareness Program, including a video to educate women and health care providers on the prevention of breast cancer by early testing for pre-cancerous breast conditions using The ForeCYTE Breast Health Test. The video is available on Atossa’s home page at www.atossagenetics.com and is being distributed directly to healthcare providers nationwide.

As the first step in the awareness program, Atossa has released the new video to inform women and their doctors about Atossa’s “Pap smear for the breast” for early detection of cancerous cells and pre-cancerous conditions. While mammograms can detect cancer, Atossa’s test detects treatable pre-cancerous conditions in the breast up to eight years before cancer arises. In women with certain pre-cancerous changes, breast cancer incidence can be reduced by as much as 86 percent with existing medical treatments.

In addition, women with dense breasts, whom research shows may be at a higher risk for breast cancer and for whom mammograms are often less reliable, can be tested easily with the ForeCYTE test in their healthcare providers’ office.

“Early testing for certain pre-cancerous conditions of the breast that, if left untreated, can lead to breast cancer, is immensely valuable to patients and their loved ones,” said Chris Destro, Vice President. “Our video(s), website, blog and interactive National Awareness Program are designed to be a new source of information for consumers and healthcare providers seeking to learn about new, non-invasive detection options, like the ForeCYTE test.”

In the video, Kathryn J. Wood, M.D., F.A.C.O.G, a Board Certified OB/GYN who now uses Atossa’s ForeCYTE Breast Health Test in her practice in the Dallas area, notes that early detection is key to saving lives and encourages her patients to be tested for pre-cancerous changes, which Atossa believes is important in reducing the incidence of breast cancer.

Updates to the Atossa National Awareness Program will be announced periodically and on CEO Dr. Steven Quay’s blog, which can be accessed through Atossa’s website at http://atossagenetics.com/blog/.

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician’s office. A small sample of fluid, aspirated from the nipple of each breast with the Company’s modified breast pump, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test and the test is painless.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a “liquid biopsy” for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with marketing plans, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa’s ability to continue to manufacture and sell its products, the efficacy of Atossa’s products and services, the market demand for and acceptance of Atossa’s products and services, performance of distributors and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed January 28, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Wellness Lubbock adds new testing to detect breast cancer even earlier

The Breast Center at Wellness Lubbock offers revolutionary new breast cancer detection and therapies. Today, Dr. Chou published an article on Lubbock Avalanche-Journal Online to inform patients and colleagues that Wellness Lubbock and the Aurora Breast Center will be offering the ForeCYTE Breast Health Test.

Dr. Chou, Radiation Oncologist Breast Care Specialist Medical Director

“Knowing your lifetime risk of breast cancer is important, and now we have the opportunity to provide this critical information,” says Dr. Chou. “This knowledge empowers women to more effectively manage and protect their breast health.”

To read the entire article, click here: Wellness Lubbock Article

Dr. Steven Quay Featured in “Insights from Industry”

In the Medical News segment “Insights from Industry”, CEO of Atossa Genetics, Dr. Steven Quay is featured on www.news-medical.net.

You can read the full article here: http://www.news-medical.net/news/20130222/Breast-cancer-tests-an-interview-with-Dr-Steven-Quay-CEO-of-Atossa-Genetics.aspx


Insights from Industry with Dr. Steven Quay of Atossa Genetics - courtesy of News-Medical.net

Mammographic Density Link to Breast Cancer

An article published on 29/1/2013 studies the very important link between breast density (found on a mammogram) and its link to breast cancer.

This article was published in Breast Cancer Research 2013, 15:R9 by Pollan et al.  - “Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study

This study took into account “invasiveness, means of detection, pathologic subtype and time elapsed since mammographic exploration and BC diagnosis”

The results clearly showed that there was a strong relationship between mammographic density and subsequent breast cancer diagnosis. The researchers reported a particularly high risk for “interval cases” (with an odds ratio of 7.72 vs. the reference category of 3.47) with an associated risk persisting for “at least 7-8 years after mammographic exploration”

To read the full study, click here: MD link to BC

We encourage all women to seek preventative medicine and learn more about their baseline breast health to find out which actions can be taken to prevent breast cancer.

Atossa Genetics and Clarity Women’s Health Announce U.S. Launch of the ForeCYTE Breast Health Test

Watch this recent video of Atossa Genetics’ CEO Dr. Steven Quay explaining the value of the ForeCYTE Breast Health Test

If this player is not working for you, please visit the link below:

Atossa Genetics CEO Dr. Steven Quay Spotlights ForeCYTE FDA cleared Breast Cancer Detection Device